Documentos relacionados

1. CD49d Is Upregulated in Circulating T Lymphocytes from HTLV-1-Infected Patients.
2. Identification of dysregulated pathways underlying HTLV-1-associated myelopathy/tropical spastic paraparesis through co-expression network analysis.
3. Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma.
4. Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis.
5. Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1).
6. Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study.
7. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
8. T helper type 9 cell response and its role in the neurological clinic of patients with Human T-lymphotropic virus 1.
9. Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series.
10. Pain, psychoaffective symptoms, and quality of life in human T cell lymphotropic virus type 1 (HTLV-1): a cross-sectional study.